Newron Pharmaceuticals S.p.A. logo

Newron Pharmaceuticals S.p.A.


Overview | Financials
Company Name Newron Pharmaceuticals S.p.A.
Symbol NWRN.SW
Currency CHF
Price 7.9
Market Cap 155,849,494
Dividend Yield 0%
52-week-range 4.09 - 11.2
Industry Biotechnology
Sector Healthcare
CEO Mr. Stefan Weber

An error occurred while fetching data.

About Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for

Related Stocks

Santhera Pharmaceuticals Holding AG logo

Santhera Pharmaceuticals Holding AG


9.34 CHF

Kuros Biosciences AG logo

Kuros Biosciences AG


13 CHF

Evolva Holding SA logo

Evolva Holding SA


0.91 CHF

Molecular Partners AG logo

Molecular Partners AG


5.93 CHF

Relief Therapeutics Holding AG logo

Relief Therapeutics Holding AG


1.16 CHF


Numbers are in millions USD

Numbers are in millions USD